Biofrontera AG
B8F.DE
Deutsche Börse6.80
EUR
+6.48
- -
Biofrontera AG
B8F.DE
(Deutsche Börse)
Recent
price
6.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biofrontera AG (B8F.DE) is a biotechnology company focused on the development, manufacture, and commercialization of photodynamic therapy solutions for dermatological conditions. The company offers Ameluz, a topical photosensitizer gel based on 20% 5-aminolevulinic acid hydrochloride used in combination with BF-RhodoLED or BF-X1 lamps for the treatment of actinic keratosis and superficial basal cell carcinoma; BF-200 ALA (Ameluz), a nanoemulsion formulation for similar indications; and medical light sources including the BF-RhodoLED panel and BF-X1 standalone lamp, all approved in Europe and other regions. Its pipeline includes additional dermatology and oncology applications leveraging photodynamic technology. Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera operates primarily in Europe, the United States, and select international markets, targeting healthcare providers such as dermatologists and oncologists in the medical dermatology segment. In recent developments, the company expanded its U.S. commercial footprint through strategic distribution partnerships and launched enhanced photodynamic therapy protocols in 2024, while pursuing further regulatory approvals for pipeline candidates amid ongoing efforts to strengthen its balance sheet via capital raises.